Patent · US Active

Formulations of hepalatide

US10603352B2 · kind B2 · utility

0Cited by
2References
18Claims
0Family size

Assignee

Inventor

Key dates

Filing dateJun 24, 2014
Grant dateMar 31, 2020
Priority date
Expiry dateJun 24, 2034

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2730/10132
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure provides a drug formulation for hepalatide, comprising hepalatide and a buffer salt, and containing or not containing an osmotic regulator and/or an excipient.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.